Annexure III - PMSMA€¦ · Inj Tetanus toxoid D14 Tab Paracetamol D3 Cap Ampicillin D9 Tab....

11
24 Pradhan Mantri Surakshit Matritva Abhiyan Annexure III 3.1: Pradhan Mantri Surakshit Matritva Abhiyan Onsite Monitoring Format State: …………………......... District: …………………......... Block: …………………......... Urban/Rural: …………………........................... Date: …./…....../…... Time of visit: .....: ..... Name of health facility: ……………...... Type of facility: DH/SDH/CHC/PHC/Private Name of monitor: ………………….......................Designation: ………………….....................Organization: ………………….................. Availability of HR/ Equipments/ Drugs/ Diagnostics Secon – A: Service Provider Informaon: Sr. No. Category Available (Yes/No) No. (s) Sr. No. Category Available (Yes/No) No. (s) A1 Obs & Gynae Specialist A4 Staff Nurses (SN) A2 Medical Officer (MO) A.4.1 Staff Nurses (Trained in SBA/ Dakshata) A2.1 CEmOc trained A5 Auxiliary Nurse Midwife (ANM) A2.2 BEmOC trained A.5.1 ANM (Trained in SBA/ Dakshata) A3 Private provider (O & G/ MO ) A6 Counsellor (RMNCH+A/SN/ANM)

Transcript of Annexure III - PMSMA€¦ · Inj Tetanus toxoid D14 Tab Paracetamol D3 Cap Ampicillin D9 Tab....

Page 1: Annexure III - PMSMA€¦ · Inj Tetanus toxoid D14 Tab Paracetamol D3 Cap Ampicillin D9 Tab. Calcium 500 mg & Vit D3 D15 Tab Chloroquine D4 Cap Amoxicillin D10 Tab. Albendazole D16

24 Pradhan Mantri Surakshit Matritva Abhiyan

Ann

exur

e III

3.1:

Pra

dhan

Man

tri S

urak

shit

Mat

ritv

a A

bhiy

an O

nsit

e M

onit

orin

g Fo

rmat

Stat

e: …

……

……

……

......

...

Dist

rict:

……

……

……

…...

......

Blo

ck: …

……

……

……

......

... U

rban

/Rur

al: …

……

……

……

......

......

......

......

...

Date

: …./

…...

.../…

... T

ime

of v

isit:

.....:

.....

Nam

e of

hea

lth fa

cilit

y: …

……

……

......

Typ

e of

faci

lity:

DH/

SDH/

CHC/

PHC/

Priv

ate

Nam

e of

mon

itor:

……

……

……

…...

......

......

......

..Des

igna

tion:

……

……

……

…...

......

......

......

Org

aniza

tion:

……

……

……

…...

......

......

...

Ava

ilabi

lity

of H

R/ E

quip

men

ts/

Dru

gs/

Dia

gnos

tics

Secti

on –

A: S

ervi

ce P

rovi

der

Info

rmati

on:

Sr.

No.

Cate

gory

Ava

ilabl

e (Y

es/N

o)N

o.

(s)

Sr.

No.

Cate

gory

Ava

ilabl

e(Y

es/N

o)N

o.

(s)

A1O

bs &

Gyn

ae S

peci

alist

A4St

aff N

urse

s (SN

)

A2M

edic

al O

ffice

r (M

O)

A.4.

1St

aff N

urse

s (Tr

aine

d in

SBA

/ Dak

shat

a)

A2.1

CEm

Oc

trai

ned

A5Au

xilia

ry N

urse

Mid

wife

(AN

M)

A2.2

BEm

OC

trai

ned

A.5.

1AN

M (T

rain

ed in

SBA

/ Dak

shat

a)

A3Pr

ivat

e pr

ovid

er

(O &

G/ M

O )

A6Co

unse

llor (

RMN

CH+A

/SN

/AN

M)

Page 2: Annexure III - PMSMA€¦ · Inj Tetanus toxoid D14 Tab Paracetamol D3 Cap Ampicillin D9 Tab. Calcium 500 mg & Vit D3 D15 Tab Chloroquine D4 Cap Amoxicillin D10 Tab. Albendazole D16

25Operational Framework

Secti

on –

B: E

ssen

tial

Equ

ipm

ent (

Veri

fy p

hysi

cally

for

avai

labi

lity

and

func

tion

alit

y)

S.

No.

Equi

pmen

t’s

& In

stru

-m

ents

Yes/

N

oN

o.Eq

uipm

ent’

s &

Inst

rum

ents

Yes/

N

oS.

N

o.Eq

uipm

ent’

s &

In-

stru

men

tsYe

s/

No

B1BP

App

arat

usB2

Adul

t ste

thos

cope

B3W

eigh

ing

mac

hine

B4He

ight

scal

eB5

Mea

surin

g ta

peB6

Torc

h

B7Th

erm

omet

erB8

Feto

scop

e/Do

pple

r for

FHS

B9St

erile

Glo

ves

Secti

on –

C: D

iagn

osti

c Se

rvic

es

(Con

firm

the

avai

labi

lity

of la

b te

sts

for

follo

win

g: W

rite

yes

for

each

labo

rato

ry s

ervi

ce a

vaila

ble

in h

ouse

.)

S. N

o.D

iagn

osti

c Se

rvic

esYe

s/ N

oN

o.D

iagn

osti

c Se

rvic

esYe

s/ N

o

C1He

mog

lobi

nC5

Poin

t of C

are

Test

for S

yphi

lis/ V

DRL/

RPR

C2U

rine

Albu

min

& S

ugar

C6W

hole

Blo

od F

inge

r Pric

k Te

st

C3Sc

reen

ing

for G

esta

tiona

l Di

abet

es M

ellit

us (O

GTT)

C7Bl

ood

Grou

ping

C4M

alar

ia th

roug

h RD

K

(in e

ndem

ic a

reas

)C8

Ultr

asou

nd In

-hou

se O

utso

urce

d

Page 3: Annexure III - PMSMA€¦ · Inj Tetanus toxoid D14 Tab Paracetamol D3 Cap Ampicillin D9 Tab. Calcium 500 mg & Vit D3 D15 Tab Chloroquine D4 Cap Amoxicillin D10 Tab. Albendazole D16

26 Pradhan Mantri Surakshit Matritva Abhiyan

Secti

on –

D: D

rugs

Ava

ilabl

e

(che

ck th

e av

aila

bilit

y of

eac

h dr

ug a

t the

PM

SMA

Clin

ic o

r ph

arm

acy.

Wri

te y

es/n

o ac

cord

ingl

y. If

ade

quat

e st

ock

not a

vaila

ble

men

tion

in y

our

rem

arks

)

S.

No.

Equi

pmen

t’s

& In

stru

-m

ents

Yes/

N

oN

o.Eq

uipm

ent’

s &

Inst

rum

ents

Yes/

N

oS.

N

o.Eq

uipm

ent’

s &

In-

stru

men

tsYe

s/

No

D1IF

A Ta

blet

sD7

Inj.

Dexa

met

haso

neD1

3Ta

b. L

abet

alol

D2Ta

b Fo

lic A

cid

D8In

j Tet

anus

toxo

idD1

4Ta

b Pa

race

tam

ol

D3Ca

p Am

pici

llin

D9Ta

b. C

alci

um 5

00 m

g &

Vit

D3D1

5Ta

b Ch

loro

quin

e

D4Ca

p Am

oxic

illin

D10

Tab.

Alb

enda

zole

D16

Tab

Nife

dipi

ne

D5Ta

b M

etro

nida

zole

D11

Tab.

Met

hyld

opa

D17

Eryt

hrom

ycin

D6Ge

ntam

icin

D12

Inj.

Labe

talo

l D1

8Ta

b Pa

race

tam

ol

Page 4: Annexure III - PMSMA€¦ · Inj Tetanus toxoid D14 Tab Paracetamol D3 Cap Ampicillin D9 Tab. Calcium 500 mg & Vit D3 D15 Tab Chloroquine D4 Cap Amoxicillin D10 Tab. Albendazole D16

27Operational Framework

Secti

on E

: Inf

rast

ruct

ure

(Con

firm

the

avai

labi

lity

of fo

llow

ing

basi

c in

fras

truc

ture

)

Sr. N

o.In

fras

truc

ture

Yes/

No

E1Cl

ean

Toile

t for

PW

E2Ad

equa

te w

aitin

g sp

ace

for w

omen

E3Pr

ovisi

on o

f drin

king

wat

er

E4Ex

amin

ation

tabl

es in

AN

C cl

inic

E5Ad

equa

te S

ign

posti

ng fo

r AN

C se

rvic

es

E6IE

C M

ater

ial o

n PM

SMA

Page 5: Annexure III - PMSMA€¦ · Inj Tetanus toxoid D14 Tab Paracetamol D3 Cap Ampicillin D9 Tab. Calcium 500 mg & Vit D3 D15 Tab Chloroquine D4 Cap Amoxicillin D10 Tab. Albendazole D16

28 Pradhan Mantri Surakshit Matritva Abhiyan

Serv

ice

Del

iver

y (C

heck

if w

omen

are

rec

eivi

ng th

e fo

llow

ing

serv

ices

)

Secti

on F

: Ide

ntific

ation

and

Man

agem

ent

of H

igh

Risk

Pre

gnan

cies

Sr. N

o.In

fras

truc

ture

Yes/

No

Yes/

No

F1W

omen

iden

tified

with

ana

emia

F5W

omen

iden

tified

as S

erop

ositi

ve fo

r HI

V

F2Ad

equa

te w

aitin

g sp

ace

for

wom

enF6

Wom

en id

entifi

ed S

erop

ositi

ve fo

r syp

hilis

F3Pr

ovisi

on o

f drin

king

wat

erF7

Wom

en id

entifi

ed w

ith h

ypot

hyro

idism

F4Ex

amin

ation

tabl

es in

AN

C cl

inic

F9W

omen

iden

tified

with

any

oth

er h

igh

risk

fact

or

F10

IFA

dist

ributi

onF1

3Tr

eatm

ent f

or D

iabe

tes

F11

Calc

ium

supp

lem

enta

tion

F14

Trea

tmen

t for

oth

er h

igh

risk

fact

ors

F12

Trea

tmen

t for

Hyp

erte

nsio

nF1

5P.W

with

hig

h ris

k fa

ctor

s ref

erre

d fo

r fur

ther

tr

eatm

ent

Page 6: Annexure III - PMSMA€¦ · Inj Tetanus toxoid D14 Tab Paracetamol D3 Cap Ampicillin D9 Tab. Calcium 500 mg & Vit D3 D15 Tab Chloroquine D4 Cap Amoxicillin D10 Tab. Albendazole D16

29Operational Framework

Secti

on G

: Cou

nsel

ling

Serv

ices

G1

Coun

selli

ng S

ervi

ces

bein

g pr

ovid

ed (Y

/N)

G2Ca

dre

Prov

idin

g Co

unse

lling

(Ple

ase

spec

ify if

RM

NCH

+A c

ouns

ello

r/SN

/AN

M p

rovi

ding

cou

nsel

ling)

G3Is

Gro

up C

ouns

ellin

g be

ing

done

(Y/N

)

G4Is

One

on

One

Cou

nsel

ling

bein

g do

ne (Y

/N)

G5Is

a C

ouns

ellin

g to

ol a

vaila

ble

(Y/N

) eg

flipb

ook/

safe

mot

herh

ood

book

let

G6Ar

e w

omen

cou

nsel

led

for B

irth

Prep

ared

ness

and

Com

plic

ation

Rea

dine

ss

G7Ar

e w

omen

cou

nsel

led

for p

ost-p

artu

m fa

mily

pla

nnin

g

G8Ar

e w

omen

cou

nsel

led

on N

utriti

on d

urin

g pr

egna

ncy

Page 7: Annexure III - PMSMA€¦ · Inj Tetanus toxoid D14 Tab Paracetamol D3 Cap Ampicillin D9 Tab. Calcium 500 mg & Vit D3 D15 Tab Chloroquine D4 Cap Amoxicillin D10 Tab. Albendazole D16

30 Pradhan Mantri Surakshit Matritva Abhiyan

Doc

umen

tati

on:

(Ple

ase

veri

fy p

hysi

cally

if t

he fo

llow

ing

reco

rds

are

avai

labl

e an

d be

ing

mai

ntai

ned)

Sr. N

o.Re

cord

Yes/

No

H1

AN

C Re

gist

er

H2Li

ne li

st o

f HRP

H3M

CP C

ards

H4PM

SMA

repo

rting

For

mat

s

Secti

on I:

Che

ck M

CP C

ards

of 5

wom

en w

ho h

ave

com

plet

ed t

heir

AN

C du

ring

the

PM

SMA

W

rite

Yes

, if t

he p

aram

eter

has

bee

n re

cord

ed

Ges

tati

onal

Age

Hem

oglo

bin

Wei

ght

BPFH

SA

bdom

inal

Exa

min

ation

USG

A

ppro

pria

te C

olor

sti

cker

Case

1

Case

2

Case

3

Case

4

Case

5

Page 8: Annexure III - PMSMA€¦ · Inj Tetanus toxoid D14 Tab Paracetamol D3 Cap Ampicillin D9 Tab. Calcium 500 mg & Vit D3 D15 Tab Chloroquine D4 Cap Amoxicillin D10 Tab. Albendazole D16

31Operational Framework

3.2:

Dis

tric

t Ass

essm

ent C

heck

list P

radh

an M

antr

i Sur

aksh

it M

atri

tva

Abh

iyan

Stat

e: ..

......

......

......

......

......

......

......

......

.. D

istr

ict:

.....

......

......

......

......

......

......

.Nam

e of

mon

itor

: ....

......

......

......

......

...

Org

aniz

ation

: ....

......

......

......

......

......

......

......

......

......

.. D

ate/

s of

vis

it: .

......

......

......

......

......

......

......

......

......

......

......

...

Mon

itor

s sh

ould

mee

t Pro

gram

me

Offi

cer

– PM

SMA

and

oth

er d

istr

ict-

leve

l offi

cers

for

advo

cacy

of P

MSM

A a

nd

also

to d

ebri

ef th

em a

bout

thei

r ob

serv

ation

s w

ith

sugg

este

d co

rrec

tive

acti

ons.

1.Is

the

initi

ative

bei

ng im

plem

ente

d in

all

bloc

ks?

If no

t, pr

ovid

e de

tails

(if

impl

emen

ted

in a

ll di

stric

ts ju

st w

rite

all).

Also

pro

vide

num

ber o

f fac

ilitie

s in

urba

n ar

eas c

orpo

ratio

ns w

here

PM

SMA

is be

ing

impl

emen

ted

......

......

... o

ut o

f ....

......

..blo

cks

......

......

......

......

......

.num

ber o

f fac

ilitie

s in

urb

an a

reas

2.St

atus

of Q

uart

erly

Dist

rict l

evel

PM

SMA

Mee

ting:

h

eld

n

ot h

eld

If h

eld,

min

utes

ava

ilabl

e?

Yes

N

o

3.a

Have

the

dist

rict o

ffici

als a

ttend

ed a

ny S

tate

leve

l orie

ntati

on?

Y

es

No

If ye

s, w

hen

was

it h

eld?

.....

......

......

......

....

3.b

Has t

he d

istric

t org

anize

d an

orie

ntati

on o

f blo

ck le

vel o

ffici

als?

Y

es

No

If ye

s, w

hen

was

it h

eld?

.....

......

......

......

..

4.N

umbe

r of h

ealth

faci

lities

whe

re c

urre

nt ro

und

of P

MSM

A is

plan

ned

to b

e co

nduc

ted

inAv

erag

e of

Cu

rren

t Qua

rter

Aver

age

of

Prev

ious

Qua

rter

4.a

Med

ical

Col

lege

s

4.b

DH

4.c

SDH

4.d

CHC/

UCH

C/ m

ater

nity

hom

es

4.e

PHC/

UPH

C

4.f

Oth

er fa

ciliti

es su

ch a

s rai

lway

hos

pita

ls et

c (n

ot fu

nded

by

NHM

but

vol

unta

rily

cond

uctin

g PM

SMA)

Page 9: Annexure III - PMSMA€¦ · Inj Tetanus toxoid D14 Tab Paracetamol D3 Cap Ampicillin D9 Tab. Calcium 500 mg & Vit D3 D15 Tab Chloroquine D4 Cap Amoxicillin D10 Tab. Albendazole D16

32 Pradhan Mantri Surakshit Matritva Abhiyan

Stat

e: ..

......

......

......

......

......

......

......

......

.. D

istr

ict:

.....

......

......

......

......

......

......

.Nam

e of

mon

itor

: ....

......

......

......

......

...

Org

aniz

ation

: ....

......

......

......

......

......

......

......

......

......

.. D

ate/

s of

vis

it: .

......

......

......

......

......

......

......

......

......

......

......

...

Mon

itor

s sh

ould

mee

t Pro

gram

me

Offi

cer

– PM

SMA

and

oth

er d

istr

ict-

leve

l offi

cers

for

advo

cacy

of P

MSM

A a

nd

also

to d

ebri

ef th

em a

bout

thei

r ob

serv

ation

s w

ith

sugg

este

d co

rrec

tive

acti

ons.

5.

Has t

he D

istric

t pla

nned

to in

volv

e Pr

ivat

e Se

ctor

in th

e PM

SMA?

Y

es

No

If ye

s, n

umbe

r of p

rivat

e pr

ovid

ers t

hat h

ave

been

invo

lved

in P

MSM

A ...

......

......

......

......

......

......

......

......

......

......

......

......

...

Have

IMA/

FO

GSI/

Rot

ary/

Lio

ns C

lub

etc

been

invo

lved

in P

MSM

A. If

yes

, pro

vide

det

ails.

......

......

......

......

......

......

......

.....

(atta

ch c

omm

ents

in se

para

te sh

eet i

f req

uire

d)

6.Ha

s the

dist

rict o

rgan

ized

a la

unch

of P

MSM

A? Y

es

No

7.If

yes,

who

laun

ched

the

PMSM

A?

8.Ho

w m

any

stat

e le

vel o

ffice

rs h

ave

been

sent

as s

tate

obs

erve

rs to

dist

ricts

in

the

curr

ent r

ound

/ pre

viou

s qua

rter

(Spe

cify

)

9.Ha

ve th

e m

onth

ly re

porti

ng fo

rmat

for P

MSM

A be

en c

omm

unic

ated

to

bloc

ks?

Yes

N

o

10.

Has t

he d

istric

t pre

pare

d an

IEC

plan

for P

MSM

A?

If ye

s, k

indl

y pr

ovid

e de

tails

Yes

N

o...

......

......

......

......

......

......

......

11.

Have

RM

NCH

+A p

artn

ers b

een

invo

lved

in th

e im

plem

enta

tion

of P

MSM

A?If

yes,

kin

dly

prov

ide

deta

ils Y

es

No

12.

Rem

arks

/Com

men

ts (4

-5 p

oint

s, w

hich

, acc

ordi

ng to

you

can

pla

y a

sign

ifica

nt ro

le in

impr

ovin

g th

e im

plem

enta

tion

of P

MSM

A in

the

dist

rict

. Als

o co

mm

ent i

f dis

tric

t ha

s in

trod

uced

any

inno

vati

ve s

trat

egy

for

impl

emen

ting

PM

SMA

.

Page 10: Annexure III - PMSMA€¦ · Inj Tetanus toxoid D14 Tab Paracetamol D3 Cap Ampicillin D9 Tab. Calcium 500 mg & Vit D3 D15 Tab Chloroquine D4 Cap Amoxicillin D10 Tab. Albendazole D16

33Operational Framework

3.3:

Sta

te A

sses

smen

t Che

cklis

t Pra

dhan

Man

tri S

urak

shit

Mat

ritv

a A

bhiy

an

Stat

e: ..

......

......

......

......

......

......

......

......

.. D

istr

ict:

.....

......

......

......

......

......

......

.Nam

e of

mon

itor

: ....

......

......

......

......

...

Org

aniz

ation

: ....

......

......

......

......

......

......

......

......

......

.. D

ate/

s of

vis

it: .

......

......

......

......

......

......

......

......

......

......

......

...

Mon

itor

s sh

ould

mee

t Pro

gram

me

Offi

cer

– PM

SMA

and

oth

er s

tate

-leve

l offi

cers

for

advo

cacy

of P

MSM

A a

nd a

lso

to d

ebri

ef th

em a

bout

thei

r ob

serv

ation

s w

ith

sugg

este

d co

rrec

tive

acti

ons.

1.N

umbe

r of D

istric

ts o

ut o

f tot

al d

istric

ts w

here

PM

SMA

is im

plem

ente

d (if

im

plem

ente

d in

all

dist

ricts

just

writ

e al

l)...

......

......

out

of .

......

.....

2.St

atus

of Q

uart

erly

Dist

rict l

evel

PM

SMA

Mee

ting:

h

eld

n

ot h

eld

If h

eld,

min

utes

ava

ilabl

e?

Yes

N

o

3.Ha

s a S

tate

leve

l orie

ntati

on o

f all

Dist

ricts

bee

n or

gani

zed?

Y

es

No

If ye

s, w

hen

was

it h

eld?

.....

......

......

......

......

..

4.N

umbe

r of h

ealth

faci

lities

whe

re c

urre

nt ro

und

of P

MSM

A ar

e co

nduc

ted

Aver

age

of

Curr

ent Q

uart

erAv

erag

e of

Pr

evio

us Q

uart

er

4.a

Med

ical

Col

lege

s

4.b

DH

4.c

SDH

4.d

CHC/

UCH

C/ m

ater

nity

hom

es

4.e

PHC/

UPH

C

4.f

Oth

er fa

ciliti

es (n

ot fu

nded

by

NHM

but

vol

unta

rily

cond

uctin

g PM

SMA)

Page 11: Annexure III - PMSMA€¦ · Inj Tetanus toxoid D14 Tab Paracetamol D3 Cap Ampicillin D9 Tab. Calcium 500 mg & Vit D3 D15 Tab Chloroquine D4 Cap Amoxicillin D10 Tab. Albendazole D16

34 Pradhan Mantri Surakshit Matritva Abhiyan

Stat

e: ..

......

......

......

......

......

......

......

......

.. D

istr

ict:

.....

......

......

......

......

......

......

.Nam

e of

mon

itor

: ....

......

......

......

......

...O

rgan

izati

on:

......

......

......

......

......

......

......

......

......

......

Dat

e/s

of v

isit

: ....

......

......

......

......

......

......

......

......

......

......

......

Mon

itor

s sh

ould

mee

t Pro

gram

me

Offi

cer

– PM

SMA

and

oth

er s

tate

-leve

l offi

cers

for

advo

cacy

of P

MSM

A a

nd a

lso

to d

ebri

ef

them

abo

ut th

eir

obse

rvati

ons

wit

h su

gges

ted

corr

ecti

ve a

ction

s.

5.

Has t

he D

istric

t pla

nned

to in

volv

e Pr

ivat

e Se

ctor

in th

e PM

SMA?

Y

es

No

If ye

s, n

umbe

r of p

rivat

e pr

ovid

ers t

hat h

ave

been

invo

lved

in P

MSM

A ...

......

......

......

......

......

......

......

......

......

......

......

......

...Ha

ve IM

A/ F

OGS

I/ R

otar

y/ L

ions

Clu

b et

c be

en in

volv

ed in

PM

SMA.

If y

es, p

rovi

de d

etai

ls....

......

......

......

......

......

......

......

...

(atta

ch c

omm

ents

in se

para

te sh

eet i

f req

uire

d)

6.Ha

s the

dist

rict o

rgan

ized

a la

unch

of P

MSM

A? Y

es

No

7.If

yes,

who

laun

ched

the

PMSM

A? C

hief

Min

ister

H

ealth

Min

ister

Oth

er (s

peci

fy)

8.Ho

w m

any

stat

e le

vel o

ffice

rs h

ave

been

sent

as s

tate

obs

erve

rs to

dist

ricts

?

If ye

s, to

how

man

y di

stric

ts.

9.Ha

ve th

e m

onth

ly re

porti

ng fo

rmat

for P

MSM

A be

en c

omm

unic

ated

to d

istric

ts?

Yes

N

o

10.

Has t

he st

ate

prep

ared

an

IEC

plan

for P

MSM

A?If

yes,

kin

dly

prov

ide

deta

ils Y

es

No

......

......

......

......

......

......

......

...

11.

Have

Sta

te R

MN

CH+A

par

tner

s bee

n in

volv

ed in

the

impl

emen

tatio

n of

PM

SMA?

If

yes,

kin

dly

prov

ide

deta

ils

Yes

N

o...

......

......

......

......

......

......

......

(atta

ch

com

men

ts in

sepa

rate

shee

t if

requ

ired)

12.

Rem

arks

/Com

men

ts (4

-5 p

oint

s, w

hich

, acc

ordi

ng to

you

can

pla

y a

sign

ifica

nt ro

le in

impr

ovin

g th

e im

plem

enta

tion

of

PMSM

A in

the

stat

e). A

lso

com

men

t if S

tate

has

intr

oduc

ed a

ny in

nova

tive

str

ateg

y fo

r im

plem

enti

ng P

MSM

A.